Resmed Acquires Noctrix Health to Enter Restless Legs Syndrome Market
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
The acquisition adds the FDA-cleared, non-pharmacologic Nidra TOMAC therapy to Resmed’s portfolio, expanding its reach into the treatment of restless legs syndrome.
More data support the concept of stroke-related restless legs syndrome as an "emerging entity," investigators report in a new study.
Available by prescription, Medi USA’s Restiffic compressive foot wrap for restless legs syndrome is FDA cleared as a Class 1 device. The drug-free therapy promotes gentle relaxing pressure on specific areas of the foot,...
Read MoreThe United States Patent and Trademark Office has issued U.S. Patent 9,017,273 to Sensory NeuroStimulation Inc covering the technologies used in Relaxis, a vibratory medical device that helps improve the quality of sleep in...
Read MoreThe US Food and Drug Administration (FDA) has granted commercial clearance for Relaxis, a...
Read More